Tamoxifen (Soltamox)

Small molecule

Approved / Phase 4Estrogen receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (3)
US
  • Reduction in Breast Cancer Incidence in Women at High Risk SOLTAMOX is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer. [see Boxed Warning and Clinical Studies (14.4) ] .
  • Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] .
Product first approved 2005FDA label
UK
  • The treatment of breast cancer; primary prevention of breast cancer in women at moderate or high risk
Product first approved 1999medicines.org.uk

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (96)
Breast Cancer
NCT04852887 · NRG Oncology
2021-06-23 – 2041-07 · Stage I Breast Cancer
What this study did
NCT07502820 · Karolinska Institutet
2026-04-14 – 2036-08 · Breast Cancer, Adjuvant Drug Therapy
What this study did
NCT06223698 · Region Örebro County
2025-05-02 – 2035-05-02 · Breast Cancer
What this study did
NCT06492616 · Stemline Therapeutics, Inc.
2024-09-27 – 2032-10 · Breast Cancer
What this study did
NCT06671912 · Alliance for Clinical Trials in Oncology
2025-02-19 – 2031-11-30 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
NCT01272037 · National Cancer Institute (NCI)
2011-02-28 – 2027-01-08 · Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
What this study did
NCT05780567 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-03-30 – 2027-01 · Breast Cancer
What this study did
NCT02062489 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2014-05 – 2026-05 · Breast Cancer
What this study did
NCT03351062 · Chinese Anti-Cancer Association
2017-11 – 2025-12 · Breast Cancer Female
What this study did
NCT00066690 · ETOP IBCSG Partners Foundation
2003-12-17 – 2024-11-06 · Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
What this study did
NCT00072462 · Queen Mary University of London
2003-09 – 2021-05-31 · Breast Cancer
What this study did
NCT02995772 · Dharmais National Cancer Center Hospital
2011-11 – 2018-11 · Breast Cancer
What this study did
NCT00004125 · Eastern Cooperative Oncology Group
1999-11-16 – 2016-11 · Breast Cancer
What this study did
NCT00659373 · ETOP IBCSG Partners Foundation
2007-12 – 2016-04 · Breast Cancer, Fatigue, Sleep Disorders
What this study did
NCT01622361 · Asan Medical Center
2012-06 – 2016-02 · Breast Cancer
What this study did
NCT00590785 · National Cancer Institute (NCI)
1996-08-13 – 2015-01-13 · High Risk, Breast Cancer, Positive Nodes, Cyclophosphamide, Doxorubicin
What this study did
NCT00002581 · Scottish Cancer Therapy Network
started 1993-06 · Breast Cancer
What this study did
NCT00002580 · Scottish Cancer Therapy Network
started 1993-06 · Breast Cancer
What this study did
NCT00002579 · Scottish Cancer Therapy Network
started 1993-03 · Breast Cancer
What this study did
NCT00002460 · Cancer Research UK
started 1987-09 · Breast Cancer
What this study did
NCT00006030 · British Association of Surgical Oncology: Breast Group
started 1992-01 · Breast Cancer
What this study did
NCT00201851 · International Breast Cancer Research Foundation
2004-01 – 2013-05 · Breast Cancer
What this study did
NCT00002720 · European Institute of Oncology
1995-12 – 2012-12 · Breast Cancer
What this study did
NCT00171704 · Novartis Pharmaceuticals
2005-04 – 2011-03 · Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
What this study did
NCT00629278 · Azienda Ospedaliero-Universitaria di Modena
2007-12 – 2010-12 · Breast Cancer
What this study did
NCT00002528 · ETOP IBCSG Partners Foundation
1993-05 – 2010-08 · Breast Cancer
What this study did
NCT00002529 · ETOP IBCSG Partners Foundation
1993-05 – 2010-08 · Breast Cancer
What this study did
NCT00002864 · NCIC Clinical Trials Group
1996-09-24 – 2010-04-23 · Breast Cancer
What this study did
NCT00005970 · National Cancer Institute (NCI)
2000-05-19 – 2010-01-27 · Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
What this study did
NCT00291759 · AstraZeneca
1996-01 – 2009-06 · Breast Cancer
What this study did
NCT00152178 · Taiho Pharmaceutical Co., Ltd.
1996-07 – 2008-08 · Breast Cancer
What this study did
NCT00002582 · Institute of Cancer Research, United Kingdom
1993-06 – 2007-04 · Breast Cancer
What this study did
NCT00309478 · Austrian Breast & Colorectal Cancer Study Group
1990-12 – 2004-06 · Early-stage Breast Cancer
What this study did
NCT00053911 · UNICANCER
2002-11 – 2004-04 · Breast Cancer
What this study did
NCT00003972 · Fred Hutchinson Cancer Center
1998-07 – 2003-03 · Breast Cancer
What this study did
NCT00793377 · GBG Forschungs GmbH
est. completion 2001-09 · Primary Breast Cancer
What this study did
NCT00309491 · Austrian Breast & Colorectal Cancer Study Group
1990-12 – 2000-03 · Early-stage Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05645536 · Tolmar Inc.
2022-12-28 – 2030-03 · Breast Cancer
What this study did
NCT01357772 · Andrea DeCensi
2008-11-12 – 2028-12-31 · Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
What this study did
NCT04906395 · Tolmar Inc.
2021-07-01 – 2027-01-30 · Breast Cancer
What this study did
NCT02097459 · Peking Union Medical College Hospital
2014-03 – 2024-03 · Breast Cancer
What this study did
NCT00601900 · National Cancer Institute (NCI)
2008-09-24 – 2024-01-29 · Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT01579734 · European Institute of Oncology
2002-03 – 2023-12 · Breast Cancer
What this study did
NCT00295646 · Austrian Breast & Colorectal Cancer Study Group
1999-06 – 2018-06-26 · Breast Cancer
What this study did
NCT00053339 · Alliance for Clinical Trials in Oncology
— · Stage IV Breast Cancer, Recurrent Breast Cancer
What this study did
NCT00004205 · ETOP IBCSG Partners Foundation
1998-03 – 2016-06-30 · Breast Cancer
What this study did
NCT00912548 · Korean Breast Cancer Study Group
2009-05 – 2015-12 · Breast Cancer
What this study did
NCT00293540 · International Breast Cancer Research Foundation
2006-02 – 2015-03 · Breast Cancer
What this study did
Phase 2/3 (4)
Breast Cancer
NCT03373708 · Zhiyong Yu
2017-12-20 – 2019-12-20 · Breast Cancer, Chemotherapy, Endocrine Breast Diseases
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02132000 · Fengxi Su
2014-04 – 2020-05 · Breast Cancer Patients in Premenopausal, Estrogen and/or Progesterone Receptor Positive
What this study did
Other / comorbidity
NCT06355401 · Sohag University
2024-04 – 2029-03 · Diffuse Large B Cell Lymphoma
What this study did
NCT02801786 · Universidade Federal de Goias
2018-11 – 2021-06 · Pain, Discomfort
What this study did
Phase 2 (143)
Breast Cancer
NCT06348134 · University of Chicago
2025-03-18 – 2036-07-01 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
What this study did
NCT02476786 · Washington University School of Medicine
2017-01-17 – 2032-07-31 · Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
What this study did
NCT07581834 · Fujian Cancer Hospital
2026-01-21 – 2032-06-30 · Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast Cancer
What this study did
NCT07101159 · Fujian Cancer Hospital
2025-09 – 2031-12 · Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
What this study did
NCT03917082 · British Columbia Cancer Agency
2019-09-23 – 2029-05-01 · Breast Cancer Female, Hormone Receptor Positive Tumor
What this study did
NCT05035836 · M.D. Anderson Cancer Center
2021-11-16 – 2028-12-29 · Breast Cancer, HER2-positive
What this study did
NCT06434064 · Roswell Park Cancer Institute
2026-03-03 – 2028-11-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT06184750 · National Cancer Institute (NCI)
2024-09-27 – 2028-09-30 · Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
What this study did
NCT06195306 · National Cancer Institute (NCI)
2025-07-28 – 2028-01-01 · Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT06001762 · Dana-Farber Cancer Institute
2023-10-05 – 2027-01-01 · Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
What this study did
NCT03161353 · MedSIR
2017-06-26 – 2026-11-01 · Breast Cancer
What this study did
NCT03879577 · University of Chicago
2019-11-25 – 2026-09-30 · Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT06033092 · European Institute of Oncology
2024-06-21 – 2026-07-31 · BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation
What this study did
NCT05150652 · Irada Ibrahim-zada
2022-02-18 – 2026-06-10 · Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
What this study did
NCT03219476 · Medical College of Wisconsin
2017-02-05 – 2025-03-20 · Breast Cancer, Invasive Breast Cancer
What this study did
NCT04038489 · University of Virginia
2019-10-18 – 2023-04-30 · Breast Cancer, Estrogen Receptor-positive Breast Cancer
What this study did
NCT01831076 · University of Colorado, Denver
2002-04 – 2022-01-06 · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
What this study did
NCT03058939 · University of Chicago
2018-11 – 2019-06 · Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT01614210 · University of Utah
2012-08 – 2016-11 · Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
What this study did
NCT00290654 · Masonic Cancer Center, University of Minnesota
2002-12 – 2013-03 · Breast Cancer
What this study did
NCT00003953 · Case Comprehensive Cancer Center
1999-02 – 2013-01 · Breast Cancer
What this study did
NCT00007904 · Case Comprehensive Cancer Center
2000-07 – 2012-09 · Breast Cancer
What this study did
NCT01194427 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011-03 – 2011-11 · Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
What this study did
NCT00764322 · UNC Lineberger Comprehensive Cancer Center
2008-06-18 – 2011-07-01 · Breast Cancer, Menopausal Symptoms
What this study did
NCT00194779 · University of Washington
2003-10 – 2011-06 · Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
What this study did
NCT00499083 · University of Nebraska
2006-05-01 – 2010-01-28 · Breast Cancer
What this study did
NCT00119262 · National Cancer Institute (NCI)
2005-10 – 2009-09 · Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
What this study did
NCT00003992 · National Cancer Institute (NCI)
1999-08 – 2009-03 · Breast Cancer
What this study did
NCT00033683 · Institute of Cancer Research, United Kingdom
started 2001-02 · Breast Cancer
What this study did
NCT00002679 · Yale University
1994-02 – 2002-01 · Breast Cancer
What this study did
NCT00003050 · University of Southern California
1997-04 – 2000-03 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05501704 · Jose Pablo Leone
2023-10-11 – 2036-04-01 · Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
What this study did
NCT02764541 · Dana-Farber Cancer Institute
2016-05-24 – 2031-04 · Breast Cancer
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT04557449 · Pfizer
2020-09-23 – 2029-10-07 · Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
What this study did
SHORTened Duration of TAMoxifenactive not recruiting
NCT07806630 · Rutgers, The State University of New Jersey
2026-09-01 – 2029-07 · High Risk for Invasive Breast Cancer
What this study did
NCT04997941 · Seoul National University Hospital
2021-10-21 – 2028-12-31 · Premenopausal Breast Cancer, Hormone Receptor-positive Breast Cancer
What this study did
NCT01196936 · University of Alabama at Birmingham
2010-09 – 2028-12-11 · Breast Cancer
What this study did
NCT07499999 · Dana-Farber Cancer Institute
2026-09-09 – 2028-08-31 · Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT02890082 · Institut Cancerologie de l'Ouest
2014-02 – 2028-01 · Breast Cancer
What this study did
NCT03707340 · Memorial Sloan Kettering Cancer Center
2018-09-14 – 2027-10-14 · Breast Cancer, Hyposexual Desire Disorder
What this study did
NCT02311933 · National Cancer Institute (NCI)
2015-05-28 – 2027-02-02 · Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT06364267 · Andrea DeCensi
2025-10-01 – 2027-01-31 · Breast Cancer
What this study did
NCT05463601 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-08-01 – 2026-12-31 · Metastatic Breast Cancer
What this study did
NCT02747004 · Eli Lilly and Company
2016-09-14 – 2026-09-09 · Metastatic Breast Cancer
What this study did
Phase 1/2 (9)
Breast Cancer
NCT01194908 · Emory University
2010-07 – 2014-01 · Breast Cancer, Breast Tumors, Breast Neoplasms
What this study did
NCT00290745 · University of California, San Francisco
2002-02-19 – 2011-06-30 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT04079517 · Karolinska Institutet
2015-03 – 2016-03 · Breast Cancer, Mammographic Density
What this study did
NCT00967824 · University of Michigan Rogel Cancer Center
2005-10 – 2008-08 · Breast Cancer
What this study did
Other / comorbidity
NCT04915846 · James Dowling
2020-12-18 – 2024-05-09 · X Linked Myotubular Myopathy
What this study did
NCT05378269 · Daré Bioscience, Inc.
2021-11-22 – 2023-03-01 · Vulvar Atrophy
What this study did
NCT02166944 · Taipei Medical University Shuang Ho Hospital
2014-04 – 2019-09-18 · Amyotrophic Lateral Sclerosis, ALS Functional Ration Scale, TAR-DNA-binding Protein-43, Tamoxifen, mTOR
What this study did
Phase 1 (30)
HR+/HER2- Metastatic Breast Cancer
NCT04174352 · University of Wisconsin, Madison
2020-10-20 – 2027-12 · ERα+ Breast Cancer, ESR1 Gene Mutation
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT04961632 · National Cancer Centre, Singapore
2020-12-23 – 2025-11 · Breast Cancer
What this study did
NCT02913430 · Shannon Puhalla
2018-04-24 – 2024-04-30 · Metastatic Breast Cancer
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT04433494 · TYK Medicines, Inc
2020-12-07 – 2023-12 · Breast Cancer, Solid Tumor
What this study did
NCT02586675 · H. Lee Moffitt Cancer Center and Research Institute
2016-02-23 – 2021-10-27 · Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
What this study did
NCT04504331 · Jennifer Lee Caswell-Jin
2020-10-13 – 2021-10-22 · Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
What this study did
NCT04080297 · Que Oncology
2014-01-10 – 2014-07-28 · Vasomotor Symptoms (VMS)
What this study did
NCT01192308 · Radboud University Medical Center
2010-07 – 2012-05 · Breast Cancer
What this study did
NCT00424164 · European Organisation for Research and Treatment of Cancer - EORTC
2006-11 – 2010-05-28 · Breast Cancer
What this study did
NCT00009997 · NYU Langone Health
1999-03 – 2004-01 · Breast Cancer
What this study did
NCT00005822 · Case Comprehensive Cancer Center
2000-04 – 2003-10 · Breast Cancer
What this study did
NCT00005886 · University of Kansas Medical Center
2000-07 – 2002-08 · Breast Cancer
What this study did
NCT00001504 · National Cancer Institute (NCI)
1996-05 – 2002-01 · Breast Cancer, Breast Neoplasm
What this study did
Other / comorbidity
NCT06942039 · C17 Council
2025-09-23 – 2032-12-31 · CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Pineoblastoma, Neuroblastoma, Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Abundant Neuropil and True Rosettes, Ependymoblastoma, Medulloepithelioma, CNS Embryonal Tumor With Rhabdoid Features, CNS Embryonal Tumor, Nos
What this study did
NCT06320990 · University of Nebraska
2025-01-22 – 2029-05 · Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
What this study did
NCT05156892 · Anthony Joshua, FRACP
2022-09-04 – 2026-11-01 · Ovarian Cancer
What this study did
NCT04200066 · University of Rochester
2022-06-01 – 2024-02-01 · Glioblastoma, Brain Tumor
What this study did
NCT02835079 · Hadassah Medical Organization
2016-11 – 2020-11 · Duchenne Muscular Dystrophy
What this study did
NCT02513849 · University of Nottingham
2015-12 – 2018-11 · Cancer, Gastrointestinal Neoplasms
What this study did
NCT01971515 · EMD Serono
2013-12-13 – 2018-08-09 · Solid Tumor
What this study did
NCT02089386 · Washington University School of Medicine
2014-07-09 – 2016-06-21 · Barrett Metaplasia
What this study did
NCT01393990 · Eli Lilly and Company
2008-09-04 – 2013-12-14 · Advanced Cancer
What this study did
NCT00749138 · Bader, Ted, M.D.
2008-11 – 2009-10 · Chronic Hepatitis C
What this study did
NCT00003080 · Fred Hutchinson Cancer Center
1996-09 – 2001-05 · Ovarian Cancer
What this study did
NCT00001436 · National Cancer Institute (NCI)
1995-05 – 2000-09 · Neoplasm Metastasis, Osteosarcoma
What this study did
Phase 4 (16)
Breast Cancer
NCT03238703 · Fred Hutchinson Cancer Center
2018-09-01 – 2025-03-14 · HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
What this study did
NCT00756717 · Loyola University
2008-02-14 – 2011-12-21 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT05525481 · Erasmus Medical Center
2022-11-01 – 2024-02-28 · ER+ Breast Cancer
What this study did
NCT02467686 · Irmandade da Santa Casa de Misericordia de Sao Paulo
2014-01 – 2017-12 · Sexuality
What this study did
NCT01612871 · Institut Claudius Regaud
2012-06-27 – 2016-01-28 · Breast Cancer
What this study did
NCT00999921 · Medical College and Hospital Kolkata
2008-01 – 2015-01 · Benign Breast Disease, Fibrocystic Disease of Breast, Fibroadenoma, Mastalgia
What this study did
NCT01553903 · Institut Claudius Regaud
2011-12 – 2013-05 · Breast Cancer
What this study did
Other / comorbidity
NCT04933240 · Virginia Commonwealth University
2022-05 – 2024-12 · Vaginal Bleeding
What this study did
NCT03060304 · Sun Yat-sen University
2017-03 – 2020-06 · Endometrium
What this study did
NCT02903121 · Oregon Health and Science University
2017-01-20 – 2019-06-05 · Bleeding, Implants, Breakthrough Bleeding
What this study did
NCT02690870 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2017-01 – 2019-03 · Infertility
What this study did
NCT02824224 · Oregon Health and Science University
2016-09-06 – 2018-01-08 · Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
What this study did
NCT02479256 · Ain Shams University
2015-06 – 2016-05 · PCOS
What this study did
NCT02070692 · Oregon Health and Science University
2014-02 – 2015-12 · Menstruation Disturbances
What this study did
Early phase / not applicable (20)
Breast Cancer
NCT01503905 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2011-12 – 2021-12 · Breast Cancer Nos Premenopausal
What this study did
NCT00538330 · King Faisal Specialist Hospital & Research Center
2007-09 – 2020-09 · Breast Cancer
What this study did
NCT01293032 · Virginia Commonwealth University
2011-04 – 2016-03 · Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
What this study did
NCT00126464 · Cedars-Sinai Medical Center
started 2004-11 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07895511 · Memorial Sloan Kettering Cancer Center
2026-10-16 – 2031-10-16 · HER2-positive Breast Cancer, Breast Cancer
What this study did
NCT07145827 · Uruk University
2024-01-02 – 2025-07-01 · Breast Cancer, Endometrial Hyperplasia and Endometrial Cancers
What this study did
NCT00963417 · ETOP IBCSG Partners Foundation
2009-08-03 – 2024-10-23 · Breast Cancer, Osteoporosis
What this study did
NCT05156606 · University Medical Center Groningen
2022-11-10 – 2024-07-31 · Male Breast Cancer
What this study did
NCT05501158 · Nalagenetics Pte Ltd
2021-01-01 – 2024-06-30 · Breast Cancer
What this study did
NCT04312347 · Nalagenetics Pte Ltd
2019-09-06 – 2021-06-30 · ER+ Breast Cancer
What this study did
NCT02488603 · National Cancer Center, Korea
2015-08 – 2018-08 · Breast Cancer
What this study did
NCT01027416 · Roswell Park Cancer Institute
2009-12-14 – 2015-12 · Breast Cancer
What this study did
NCT01075802 · Western Sydney Local Health District
2010-03 – 2012-12 · Breast Cancer, CYP2D6 Polymorphism
What this study did
NCT00847366 · AEterna Zentaris
2008-05 – 2012-12 · Non Small Cell Lung Cancer, Solid Tumors, Metastatic Breast Cancer, Sarcomas
What this study did
NCT00165308 · Dana-Farber Cancer Institute
2001-04 – 2009-06 · Hodgkin's Disease, Breast Cancer
What this study did
Other / comorbidity
NCT04292886 · Nanjing University
2019-10-01 – 2021-11-30 · Thin Endometrium
What this study did
NCT02979301 · Mayo Clinic
2017-03-01 – 2018-11-01 · High Background Uptake on MBI
What this study did
NCT00449514 · Shaare Zedek Medical Center
started 2007-05 · Infertility
What this study did
Used as active comparator (50)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (26)
Breast Cancer
NCT05952557 · AstraZeneca
2023-10-05 – 2037-05-06 · Breast Cancer, Early Breast Cancer
What this study did
NCT05774951 · AstraZeneca
2023-03-31 – 2036-05-29 · Breast Cancer, Early Breast Cancer
What this study did
NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC
2023-12-15 – 2035-11-01 · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
NCT07190443 · Japanese Foundation for Cancer Research
2025-02-07 – 2035-02-06 · Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
What this study did
NCT07349069 · Shandong Suncadia Medicine Co., Ltd.
2026-03-04 – 2034-01 · Breast Cancer
What this study did
NCT07019363 · Fudan University
2025-06-15 – 2033-04-15 · Breast Cancer, Adjuvant Therapy
What this study did
NCT05514054 · Eli Lilly and Company
2022-10-04 – 2032-03 · Breast Neoplasms
What this study did
NCT04134598 · Azienda Ospedaliero-Universitaria Careggi
2021-02-08 – 2030-03-31 · Breast Cancer
What this study did
NCT02914158 · First Affiliated Hospital, Sun Yat-Sen University
2016-03-30 – 2025-12 · Breast Cancer
What this study did
NCT00412022 · National Cancer Institute, Naples
2004-03 – 2024-11 · Breast Cancer
What this study did
NCT00053898 · NSABP Foundation Inc
2003-01 – 2016-05 · Breast Cancer
What this study did
NCT00038467 · Pfizer
1998-02 – 2013-03 · Breast Neoplasms
What this study did
NCT00605267 · AstraZeneca
2007-10 – 2010-12 · Breast Cancer
What this study did
NCT00279448 · Pfizer
2002-01 – 2009-06 · Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05306340 · Genentech, Inc.
2022-08-03 – 2027-06-15 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT00066703 · ETOP IBCSG Partners Foundation
2003-11-03 – 2024-10-23 · Breast Cancer
What this study did
NCT03137368 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2018-08-09 – 2023-10-30 · CYP2D6 Polymorphism
What this study did
NCT01758146 · Post Graduate Institute of Medical Education and Research, Chandigarh
2012-01 – 2020-06 · Breast Cancer
What this study did
NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC
2007-02 – 2020-03 · Breast Cancer
What this study did
NCT01638247 · GBG Forschungs GmbH
2012-08 – 2018-05 · Male Breast Cancer
What this study did
NCT00003906 · NSABP Foundation Inc
1999-05 – 2012-08 · Breast Cancer
What this study did
NCT00241449 · AstraZeneca
1998-11 – 2012-01 · Breast Cancer, Metastasis
What this study did
NCT00286117 · AstraZeneca
1998-03 – 2006-05 · Breast Cancer
What this study did
Other / comorbidity
NCT06404775 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-01-16 – 2030-05-16 · Mastalgia
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02101788 · National Cancer Institute (NCI)
2014-04-11 – 2025-10-27 · Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
What this study did
Phase 2 (18)
Breast Cancer
NCT05472792 · UNC Lineberger Comprehensive Cancer Center
2022-05-17 – 2032-04-15 · Breast Cancer, Quality of Life
What this study did
NCT05941520 · National Cancer Institute (NCI)
2024-10-10 – 2028-09-01 · Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT00287534 · AstraZeneca
1996-11 – 2004-09 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07729046 · University of California, San Diego
2027-07 – 2035-06 · Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05982093 · SOLTI Breast Cancer Research Group
2023-02-03 – 2026-12 · Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
What this study did
NCT05659563 · MedSIR
2023-07-20 – 2025-01-30 · Breast Cancer, Breast Cancer, Early-Onset
What this study did
NCT04059484 · Sanofi
2019-10-22 – 2025-01-02 · Breast Cancer Metastatic
What this study did
NCT05101564 · Jennifer Lee Caswell-Jin
2023-03-20 – 2024-06-03 · Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
What this study did
NCT00738777 · The Netherlands Cancer Institute
2008-07 – 2024-06 · Breast Cancer
What this study did
NCT03024580 · Instituto Nacional de Cancer, Brazil
2017-03-06 – 2020-09 · Breast Neoplasm
What this study did
NCT00728949 · Eli Lilly and Company
2008-08 – 2015-02 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT06075953 · QuantumLeap Healthcare Collaborative
2024-02-17 – 2033-11 · Ductal Carcinoma in Situ
What this study did
NCT02228681 · GOG Foundation
2015-05-21 – 2024-08-22 · Advanced, Persistent, or Recurrent Endometrial Cancer
What this study did
NCT02993159 · Northwestern University
2017-05-31 – 2022-01-24 · Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
What this study did
NCT02584465 · ARCAGY/ GINECO GROUP
2015-08-28 – 2021-09-19 · Ovarian Carcinoma
What this study did
NCT00637871 · AstraZeneca
2002-11 – 2005-08 · Gynaecomastia, Prostate Cancer
What this study did
Phase 1 (1)
HR+/HER2- Metastatic Breast Cancer
NCT02936206 · Icahn School of Medicine at Mount Sinai
2016-10 – 2020-05-01 · Breast Cancer
What this study did
Phase 4 (2)
Breast Cancer
NCT02344940 · Shanghai Jiao Tong University School of Medicine
2014-12 – 2018-08 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT00537771 · AstraZeneca
2007-09 – 2011-12 · Breast Cancer
What this study did
Early phase / not applicable (2)
HR+/HER2- Metastatic Breast Cancer
NCT00827307 · Zhejiang Cancer Hospital
2008-06 – 2011-08 · Mammography, Estrogen, Lipemia, Endometrium, Ultrasonography
What this study did
NCT01157026 · Malaysia Palm Oil Board
2001-11 – 2010-01 · Breast Cancer
What this study did
Appears in other studies (16)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (11)
Breast Cancer
NCT00310180 · National Cancer Institute (NCI)
2006-04-07 – 2030-09-30 · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
What this study did
NCT00003857 · Radiation Therapy Oncology Group
1999-12 – 2022-05-20 · Breast Cancer
What this study did
NCT00929591 · SWOG Cancer Research Network
1989-05 – 2010-03 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06507618 · University of Virginia
2024-07-19 – 2034-03-01 · Breast Cancer Female
What this study did
NCT04584853 · Institute of Cancer Research, United Kingdom
2020-12-23 – 2030-10 · Breast Cancer Female
What this study did
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT06440967 · Astellas Pharma Global Development, Inc.
2024-07-31 – 2028-04-30 · Hot Flashes
What this study did
NCT03423199 · National Cancer Center, Japan
2018-02-09 – 2025-09 · Breast Neoplasms
What this study did
NCT02278120 · Novartis Pharmaceuticals
2014-11-20 – 2023-04-20 · Advanced Metastatic Breast Cancer
What this study did
NCT00002920 · SWOG Cancer Research Network
1997-03 – 2009-12 · Breast Cancer, Endometrial Cancer
What this study did
Other / comorbidity
NCT07762885 · Fudan University
2026-07-01 – 2036-06 · Ductal Carcinoma In Situ, DCIS
What this study did
Phase 2/3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT00684216 · The Netherlands Cancer Institute
2008-04 – 2013-05 · Breast Cancer
What this study did
Phase 2 (1)
Breast Cancer
NCT04272801 · Shayna Showalter, MD
2020-04-07 – 2026-06-01 · Breast Cancer Female
What this study did
Phase 1/2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT02285179 · The Netherlands Cancer Institute
2014-11 – 2022-05-01 · Breast Cancer
What this study did
Phase 4 (2)
Breast Cancer
NCT01127295 · Institut Claudius Regaud
2010-06-17 – 2017-12-01 · Hormono-depending Adjuvant Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tamoxifen (Soltamox): this drugApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(37 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tamoxifen (Soltamox) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT04174352 · CT.gov ↗
What to watch
Phase 2Glioblastoma MultiformeRecruiting
Est. primary completion 2026-12 · NCT04765098 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
2027 (11)
January 2027 (4)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-01-01 · NCT06195306 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-30 · NCT04906395 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT06364267 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Pancreatic NeoplasmsRecruiting
Est. primary completion 2027-02-28 · NCT06914674 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Cystic Fibrosis - CompleteRecruiting
Est. primary completion 2027-06-30 · NCT07289035 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07499999 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-14 · NCT03707340 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
2028 (9)
February 2028 (1)
Early phase / not applicableBreast CancerRecruiting
Est. primary completion 2028-02 · NCT04740697 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-03-31 · NCT06184750 · CT.gov ↗
What to watch
Phase 3InfertilityRecruiting
Est. primary completion 2028-03-31 · NCT03011684 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-07 · NCT07806630 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09 · NCT06361940 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1Pancreatic Cyst, Pancreatic Mucinous Cystic NeoplasmRecruiting
Est. primary completion 2028-11 · NCT06320990 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-11-30 · NCT06434064 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-29 · NCT05035836 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10-07 · NCT04557449 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Hypogonadism, Prostate CancerRecruiting
Est. primary completion 2030-10 · NCT07535905 · CT.gov ↗
What to watch
December 2030 (1)
Phase 1CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood, Medulloblastoma, Group 3 …Recruiting
Est. primary completion 2030-12-31 · NCT06942039 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2031-04-08 · NCT04852887 · CT.gov ↗
What to watch
October 2031 (1)
Early phase / not applicableBreast CancerRecruiting
Est. primary completion 2031-10-16 · NCT07895511 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07101159 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
2036 (1)
August 2036 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2036-08 · NCT07502820 · CT.gov ↗
What to watch

See the full readout calendar ↗